Stonebranch Universal Connector Achieves SAP® Certified Integration for RISE with SAP S/4HANA® Cloud
Stonebranch strengthens its partnership with SAP through a certified integration for RISE with SAP S/4HANA Cloud, empowering enterprise automation across hybrid IT environments.
Stonebranch, a leading provider of service orchestration and automation solutions, announced today that its Universal Connector for SAP has achieved SAP® certification as integrated with RISE with SAP S/4HANA® Cloud. The integration helps organizations to centrally orchestrate automated workloads across all SAP applications and beyond.
"Our longstanding partnership with SAP reflects our commitment to empowering enterprises with sophisticated automation solutions," said Giuseppe Damiani, Stonebranch CEO. "This certification for SAP RISE with SAP S/4HANA Cloud further strengthens our ability to support hybrid IT environments by offering centralized automation and unparalleled observability for mission-critical operations."
Available on the SAP Store, the Universal Connector for SAP is a feature-rich direct integration between Stonebranch Universal Automation Center (UAC) and SAP RISE with SAP S/4HANA Cloud. This certification builds upon Stonebranch’s numerous existing SAP automation integrations, including its previously certified integration for SAP S/4HANA. By leveraging these integrations, organizations can:
- Reduce complexity and achieve end-to-end visibility of SAP S/4HANA Cloud workloads and non-SAP workloads.
- Centrally automate on-premises, cloud, and containerized systems.
- Gain actionable insights through system-wide business intelligence, analytics, and observability.
- Seamlessly transfer data between SAP application servers, non-SAP servers, and cloud platforms.
The SAP Integration and Certification Center (SAP ICC) has certified that the integration software for Stonebranch UAC v7.7 integrates with RISE with SAP S/4HANA Cloud using standard integration technologies.
About Stonebranch
Stonebranch builds IT orchestration and automation solutions that transform business IT environments from simple IT task automation into sophisticated, real-time business service automation. No matter the degree of automation, the Stonebranch platform is simple, modern, and secure. Using UAC, enterprises can seamlessly orchestrate workloads and data across technology ecosystems and silos. Headquartered in Atlanta, Georgia, with points of contact and support throughout the Americas, Europe, and Asia, Stonebranch serves some of the world’s largest financial, manufacturing, healthcare, travel, transportation, energy, and technology institutions.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107609386/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agile Data Engine Announces Built on Databricks Partner Status9.1.2025 10:15:00 CET | Press release
ADE can now embed its software solutions even deeper into the Databricks ecosystem to help companies develop, automate and deploy data lakehouses Agile Data Engine (ADE), provider of the all-in-one SaaS DataOps Development and Operations Platform for development, provision and operation of data lakehouses, has now been awarded Built on Partner status by Databricks, the Data and AI company. ADE has become a Nordic powerhouse for helping customers to move legacy data platforms to agile and resilient data lakehouses. The company offers accelerated tools that reduce implementation time and labor, helping businesses realize value more quickly by streamlining the complex process of data platform transformation and providing efficient development and operational capabilities for data lakehouses. The Databricks Data Intelligence Platform democratizes access to analytics and intelligent applications by marrying customers’ data with powerful AI models tuned to the unique characteristics of their
Infobip Recognized as AIT Fraud Prevention Leader by Juniper Research9.1.2025 10:01:00 CET | Press release
Global cloud communications platform Infobip has been recognized as the number one provider among Established Leaders in the Artificially Inflated Traffic (AIT) Fraud Prevention market by Juniper Research. The analyst firm has ranked Infobip first of 18 vendors in its Competitor Leaderboard for AIT Fraud Detection Solution Vendors 2024. Juniper Research scores vendors across 11 criteria, including but not limited to their size of operations in the AIT prevention market, the extent and breadth of relevant partnerships, market coverage, and product strength. Infobip scored highly across each of these and three further categories. Overall, Infobip was ranked as the Leading firm because it offers a comprehensive solution to AIT fraud detection and prevention strategies, including its ‘Infobip Signals’ solution, which detects AIT by monitoring phone number behavior, ranges, and types. Helping set Infobip aside from others in the market is its use of artificial intelligence (AI) and machine
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy9.1.2025 09:00:00 CET | Press release
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for thetreatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy. “Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddl
Azafaros to Present at J.P. Morgan’s 43rd Annual Healthcare Conference9.1.2025 08:37:00 CET | Press release
Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann Pick type C (NPC). Positive topline data reported earlier this year from the company’s successful Phase 2 study investigating nizubaglustat in GM2 and NPC patients demonstrated that the compound had a positive safety profile. Preliminary improvements or stabilization of clinical endpoints were observed in the majority of patients, highlighting encouraging early efficacy trends for the compound. Azafaros is preparing to initiate Phase 3 studies with nizubaglustat in
Kaneka Acquires EndoStream Medical Ltd.9.1.2025 06:21:00 CET | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) acquired 96.8% of shares of EndoStream Medical Ltd. (Headquarters: Or Akiva, Israel; CEO: Danel Mayer; hereinafter referred to as ESM), an Israeli medical equipment company, on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus™ device for aneurysm treatment currently under development. We aim to achieve sales of over 20 billion yen by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108226003/en/ Cerebral aneurysm treatment device “Nautilus™” (Graphic: Business Wire) ESM is a manufacturer of innovative technologies in the field of cerebrovascular diseases and is developing a device for the treatment of cerebral aneurysms called “Nautilus™” that can treat aneurysms with wide openings in cerebr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom